Introduction: There have been conflicting results for the high-intensity statin in reducing major adverse cardiac events (MACE) in asian patients who experienced acute myocardial infarction (AMI).
Aim of study: The aim of our study was to investigate the clinical effects of high-intensity compared to moderate-intensity statin in Korean Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH) patients.
Methods: Between November 2011 and July 2015, a total of 10,770 patients [63.3±12.5 years, male 8065 (74.9%)] were enrolled in KAMIR-NIH. Patients were divided into two groups (group I: high-intensity statin, n=3692, group II: moderate-intensity statin, n=7078, table 1) according to the intensity of statin which was used for secondary prevention after AMI. The primary endpoint was composite of MACE including all cause death, MI, repeat revascularization during the 6-month clinical follow-up. The secondary endpoint was the composite of cardiac death, MI, revascularization, cerebrovascular accidents and stent thrombosis.
Results: The incidence of primary endpoints and secondary endpoints were not different between the two groups (table 2). However, the incidence of all cause death and non-cardiac death was higher in moderate-intensity statin group (table 2).
Conclusions: The present study showed that high-intensity statin have clinical benefit by mortality reduction during 6-month clinical follow up. The benefit of high-intensity statin was observed in asian post-AMI patients.